首页|胃泌素释放肽前体、鳞状细胞癌抗原在非小细胞肺癌中的表达及临床意义

胃泌素释放肽前体、鳞状细胞癌抗原在非小细胞肺癌中的表达及临床意义

扫码查看
目的 探讨胃泌素释放肽前体(ProGRP)、鳞状细胞癌抗原(SCCA)在非小细胞肺癌(NSCLC)中的表达及临床意义.方法 选取122例NSCLC患者和93例健康体检者,分别作为观察组和对照组.采用化学发光法检测两组受试者血清ProGRP、SCCA水平,比较不同组织学类型NSCLC患者ProGRP、SCCA的水平和阳性表达率,比较两组受试者和不同临床特征NSCLC患者的ProGRP、SCCA阳性表达率.绘制受试者工作特征(ROC)曲线,计算曲线下面积(AUC),分析ProGRP、SCCA单独及联合检测对NSCLC的诊断价值.结果 鳞状细胞癌患者的血清SCCA水平高于腺癌及大细胞癌患者,差异均有统计学意义(P﹤0.05).鳞状细胞癌患者SCCA的阳性表达率高于腺癌患者,差异有统计学意义(P﹤0.05).观察组患者ProGRP、SCCA的阳性表达率分别为90.98%、78.69%,分别明显高于对照组的8.60%、6.45%,差异均有统计学意义(P﹤0.01).有淋巴结转移NSCLC患者ProGRP、SCCA的阳性表达率均明显高于无淋巴结转移患者(P﹤0.01).ROC曲线显示,ProGRP联合SCCA检测诊断NSCLC的AUC为0.797(95%CI:0.714~0.880),灵敏度为90.59%,特异度为89.25%,均高于二者单独检测.结论 ProGRP、SCCA在NSCLC患者中阳性表达率均较高,且其表达与淋巴结转移有关,二者联合检测对NSCLC具有较高的诊断价值.
Expression and clinical significance of pro-gastrin-releasing peptide and squamous cell carcinoma antigen in non-small cell lung cancer
Objective To investigate the expression and clinical significance of pro-gastrin-releasing peptide(ProGRP)and squamous cell carcinoma antigen(SCCA)in non-small cell lung cancer(NSCLC).Method A total of 122 NSCLC patients and 93 healthy subjects were selected as the observation group and the control group.The serum ProGRP and SCCA levels in the two groups were detected by chemiluminescence method.The levels and positive expres-sion rates of ProGRP and SCCA in NSCLC patients with different histological types were compared,the positive expres-sion rates of ProGRP and SCCA in the two groups and NSCLC patients with different clinical features were also com-pared.Draw the receiver operating characteristic(ROC)curve,calculate the area under the curve(AUC),and evaluate the diagnostic value of ProGRP and SCCA single and combined detection for NSCLC.Result The serum SCCA level in squamous cell carcinoma patients were higher than those in adenocarcinoma and large cell carcinoma patients,and the dif-ferences were statistically significant(P<0.05).The positive expression rate of SCCA in squamous cell carcinoma pa-tients was higher than that in adenocarcinoma patients,and the difference was statistically significant(P<0.05).The posi-tive expression rates of ProGRP and SCCA in the observation group were 90.98%and 78.69%,which were significantly higher than 8.60%and 6.45%in the control group,and the differences were statistically significant(P<0.01).The positive expression rates of ProGRP and SCCA in NSCLC patients with lymph node metastasis were significantly higher than those in patients without lymph node metastasis,and the differences were statistically significant(P<0.01).ROC curve showed that the AUC of ProGRP combined with SCCA detection for the diagnosis of NSCLC was 0.797(95%CI:0.714-0.880),the sensitivity was 90.59%,and the specificity was 89.25%,which were higher than the individual detection.Con-clusion The positive expression rates of ProGRP and SCCA in NSCLC patients are high,and their expression are associ-ated with lymph node metastasis.ProGRP and SCCA combined detection has high diagnostic value for NSCLC.

non-small cell lung cancerpro-gastrin-releasing peptidesquamous cell carcinoma antigen

白咪红、崔雅婷、魏宝、曹喻

展开 >

宝鸡市人民医院检验科,陕西 宝鸡 721000

宝鸡市人民医院肿瘤外科,陕西 宝鸡 721000

遵义医科大学附属医院检验科,贵州 遵义 563099

非小细胞肺癌 胃泌素释放肽前体 鳞状细胞癌抗原

贵州省科技计划项目

黔科合LH字[2017]7097号

2024

癌症进展
中国医学科学院,北京协和医学院

癌症进展

影响因子:1.004
ISSN:1672-1535
年,卷(期):2024.22(1)
  • 15